New drug developed to treat Alzheimer’s disease

Medicine has advanced more than at any time in the last hundred years. Today, science has been extremely successful in curing many diseases and overcoming many diseases. Undoubtedly, medical science plays a big role in increasing the average life expectancy of mankind and improving the quality of human life. However, even today there are some incurable diseases for which medicine cannot find a cure. Alzheimer’s disease is one such disease. Today, millions of people around the world suffer from dementia and its most common form, Alzheimer’s disease. On the other hand, an event has occurred that may give hope to Alzheimer’s patients in the coming period…

For the first time in the world, a drug has been developed that slows down the destruction of Alzheimer’s disease in the brain. It was stated that the results of clinical trials of the drug “Lecanemab” marked the beginning of a new era in the fight against Alzheimer’s disease. This revolutionary development, which greatly excited scientists, could be considered a historic success. Let’s look at the details together…

Alzheimer’s disease is usually observed in the elderly, which grossly reduces the cognitive abilities of a person and therefore causes the disappearance of even vital functions such as speech, walking and the like.

Scientists have been making intensive efforts to treat this disease for many years. However, most of the work done so far has not been successful. For this reason, even though some drugs were used by Alzheimer’s patients, there was no drug that could change the course of the disease.

A drug called Lekanemab, developed by United States biotech companies Biogen and Japan’s Eisai, has been shown to slow the brain-destroying disease process.

A drug tested in clinical trials at the University College London (UCL) Dementia Research Institute was found to slow cognitive decline in the early stages of the disease. Thus, a new era has begun in the treatment of Alzheimer’s disease, the most common form of dementia.

About 1800 patients with early stage Alzheimer’s disease took part in clinical trials of the drug.

Some patients in the study were regularly given Lecanemab. At the end of the study, the drug was seen to reduce mental decline in Alzheimer’s patients by 27 percent over 18 months. While “27 percent” may seem like a low number, it’s very promising given that most Alzheimer’s studies have ended in complete failure.

Lecanemab targets a sticky substance called beta-amyloid, which is produced in the brains of Alzheimer’s patients.

This substance, called beta-amyloid, which is mainly composed of protein, accumulates in the brain of patients and forms plaques, and these plaques settle in the spaces between neurons. Previous research has shown that these plaques cause brain cell death. Lecanemab targets this substance called beta-amyloid…

Scientists claim that the drug Lecanemab is effective in the early stages of Alzheimer’s disease.

For this reason, people whose disease cannot be detected at an early stage are unlikely to benefit from this revolutionary treatment.

John Hardy, the scientist who put forward the idea 30 years ago that amyloids should be targeted to treat Alzheimer’s disease, called the results “historic”.

Hardy comments on this new development, “I am optimistic that we will see the beginning of treatment for Alzheimer’s disease.” explained from his words. However, prof. Tara Spears-Jones said:These results are very important as our bounce rate has been at 100% for a long time.he made a statement. Many scientists are of the opinion that thanks to this new developed drug, Alzheimer’s disease can cease to be an incurable disease.

Source: 1